These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 11665725)

  • 41. Resin lacquer: a cheaper alternative to amorolfine for onychomycosis?
    Yong AS
    Br J Dermatol; 2015 Oct; 173(4):888-9. PubMed ID: 26511823
    [No Abstract]   [Full Text] [Related]  

  • 42. Onychomycosis: burden of disease and the role of topical antifungal treatment.
    Daniel RC
    J Drugs Dermatol; 2013 Nov; 12(11):1263-6. PubMed ID: 24196334
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of user-friendliness and treatment cost of Loceryl® vs. Ciclopoli®--a patient's perspective.
    Schaller M; Braunsdorf C; Mailänder-Sanchez D; Jäckel A; Müller J; Borelli C
    Mycoses; 2015 Oct; 58(10):632-6. PubMed ID: 26393437
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ciclopirox: recent nonclinical and clinical data relevant to its use as a topical antimycotic agent.
    Subissi A; Monti D; Togni G; Mailland F
    Drugs; 2010 Nov; 70(16):2133-52. PubMed ID: 20964457
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ciclopirox (Penlac) nail lacquer for onychomycosis.
    Med Lett Drugs Ther; 2000 Jun; 42(1080):51-2. PubMed ID: 10859733
    [No Abstract]   [Full Text] [Related]  

  • 46. Today's treatments options for onychomycosis.
    Iorizzo M; Piraccini BM; Tosti A
    J Dtsch Dermatol Ges; 2010 Nov; 8(11):875-9. PubMed ID: 20738460
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Optimized Ciclopirox-Based Eudragit RLPO Nail Lacquer: Effect of Endopeptidase Enzyme as Permeation Enhancer on Transungual Drug Delivery and Efficiency Against Onychomycosis.
    Khattab A; Shalaby S
    AAPS PharmSciTech; 2018 Apr; 19(3):1048-1060. PubMed ID: 29138987
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Topical and surgical treatment of onychomycosis.
    Cohen PR; Scher RK
    J Am Acad Dermatol; 1994 Sep; 31(3 Pt 2):S74-7. PubMed ID: 8077513
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Report of a case of a dermatophytoma successfully treated with topical efinaconazole 10% solution.
    Cantrell W; Canavan T; Elewski B
    J Drugs Dermatol; 2015 May; 14(5):524-6. PubMed ID: 25942674
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical practice. Fungal nail disease.
    de Berker D
    N Engl J Med; 2009 May; 360(20):2108-16. PubMed ID: 19439745
    [No Abstract]   [Full Text] [Related]  

  • 51. Long-term follow-up of toenail onychomycosis caused by dermatophytes after successful treatment with systemic antifungal agents.
    Piraccini BM; Sisti A; Tosti A
    J Am Acad Dermatol; 2010 Mar; 62(3):411-4. PubMed ID: 20159308
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Therapies for onychomycosis: a review.
    Gupta AK; Tu LQ
    Dermatol Clin; 2006 Jul; 24(3):375-9. PubMed ID: 16798436
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of a new medicated nail hydrolacquer in the treatment of adults with toenail onychomycosis: A randomised clinical trial.
    Zalacain-Vicuña AJ; Nieto C; Picas J; Martínez H; Bermejo R; Corrales A; Campos FF; Igea SA; Otero-Espinar FJ; Briones VG
    Mycoses; 2023 Jul; 66(7):566-575. PubMed ID: 36336989
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Assessing treatment outcomes in toenail onychomycosis clinical trials.
    Werschler WP; Bondar G; Armstrong D
    Am J Clin Dermatol; 2004; 5(3):145-52. PubMed ID: 15186193
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Economic analysis of oral and topical therapies for onychomycosis of the toenails and fingernails.
    Casciano J; Amaya K; Doyle J; Arikian S; Shear N; Haspel M; Kahler K
    Manag Care; 2003 Mar; 12(3):47-54. PubMed ID: 12685377
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Trichophytum rubrum endonyx onychomycosis resistant to standard oral and topical therapies.
    Mulvaney PM; Telang GH; Jellinek N
    Dermatol Online J; 2015 Sep; 21(9):. PubMed ID: 26437286
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Establishment of a novel model of onychomycosis in rabbits for evaluation of antifungal agents.
    Shimamura T; Kubota N; Nagasaka S; Suzuki T; Mukai H; Shibuya K
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3150-5. PubMed ID: 21555762
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ciclopirox topical solution, 8% combined with oral terbinafine to treat onychomycosis: a randomized, evaluator-blinded study.
    Gupta AK;
    J Drugs Dermatol; 2005; 4(4):481-5. PubMed ID: 16004022
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A randomized comparison of nail surface remanence of three nail lacquers, containing amorolfine 5%, ciclopirox 8% or tioconazole 28%, in healthy volunteers.
    Sidou F; Soto P
    Int J Tissue React; 2004; 26(1-2):17-24. PubMed ID: 15573688
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hydrosoluble medicated nail lacquers: in vitro drug permeation and corresponding antimycotic activity.
    Monti D; Saccomani L; Chetoni P; Burgalassi S; Senesi S; Ghelardi E; Mailland F
    Br J Dermatol; 2010 Feb; 162(2):311-7. PubMed ID: 19886884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.